Introduction
Breast cancer-the most common noncutaneous cancer among women in the United States-kills more women every year than nearly all other cancers, falling only second to lung cancer. (1, 2) Surveillance estimates suggest over 230 000 women will be diagnosed with breast cancer in 2014, and the disease will claim an estimated 40 000 lives. (3) In the 1980s and 1990s, the incidence of diagnosed breast cancer rose due to an increase in 
Risk Assessment for Breast Cancer
Risk factor assessment is critically important for breast cancer screening. Women should be divided into high risk or average risk categories to guide screening options and risk reduction strategies.
While screening programs traditionally use age as the primary risk factor, the individual's collective risk factors determine the net benefits and harms of additional screening, such as genetic testing, or interventions to reduce risk, such as chemoprevention.
Risk Factors
Age. 
Tobacco
Studies have shown a strong association between current and previous tobacco use and risk of breast cancer. In a prospective cohort study of almost 80 000 women, current smokers had a 16% higher risk of breast cancer and former smokers had a 9% increased risk over non-smokers. This increased breast cancer risk remained up to 20 years after smoking cessation. For nonsmokers, a very high exposure to passive smoking (defined as ≥10 years' exposure in childhood, ≥ 20years' exposure as an adult at home, and ≥10 years' exposure as an adult at work) resulted in a 32% increased risk of breast cancer compared with those never exposed to secondhand smoke. (41) Another study including nearly 3000 women found a significant increased risk of all-cause mortality in women who smoked either 15-24 cigarettes or 25+ cigarettes per day, with the highest risk for women who smoked the highest quantity.
Overall, women who smoked for 20+ pack-years had a 54% increase in breast cancer mortality and an 81% increase in all-cause mortality. (60) Other trials have also failed to show a mortality benefit for raloxifene, but notably, they lacked sufficient power to detect significant differences in mortality over their course of follow-up. (61, 62) An updated meta-analysis of over 80 000 women found that 4 SERMS (tamoxifen, raloxifene, arzoxifene, and lasofoxifene) reduced breast cancer by 38% compared to the control group. An increased rate of endometrial cancer was mostly limited to the tamoxifen trials. Risk for venous thromboembolism was similar between tamoxifene and raloxifene, with a slightly increased rate with arzoxifene and lasofoxifene. All SERMS had similar risk reduction for fractures, and no effect of SERMs was found for myocardial infarction, stroke, or transient ischemic attacks. (54 continue to recommend routine screening in women 40 to 49. These groups cite evidence that the mortality risk reduction associated with screening younger women is comparable to the benefit observed in screening older women (69) (70) (71) . They also judged that the balance of benefits and harms favored a strategy of routine screening for all younger women. In addition, a large case control study published after release of the USPSTF and CTFPHC guidelines suggests a lack of screening in women aged 40 to 49 years is associated with a higher death rate from breast cancer. Among 609 confirmed breast cancer deaths, 71% occurred in women who were not screened regularly while 29% occurred in women who had been screened with mammography. In this study, the death rate from breast cancer was actually higher in women aged <50 years compared to women aged ≥50 years. 
Breast Ultrasound
Breast ultrasound has been studied particularly for screening women with high breast density due to the lower sensitivity of mammography in these patients. One study found that 42% of all women with nonpalpable invasive breast cancer had their cancers detected only with screening ultrasound, and 37% of all cancers in women with dense breasts were detected only with screening ultrasound. (81) In another study of women with dense breast tissue who received either mammography plus ultrasound or mammography alone, supplemental ultrasound detected an additional 4.2 cancers per 1000 women. (82) While these studies show promising results for the use of ultrasound in women with high breast density, at this time there is no recommendation for performing ultrasound as part of routine breast cancer screening.
Breast Self-Examination
A few large trials have analyzed the effect of instructing women in breast self-examination (BSE) 
Clinical Breast Examination
The efficacy of the clinical breast examination (CBE) has been investigated in a few large trials. In community settings assessing CBE as part of the National Early Detection Program, CBE detected 5.1%
of breast cancers that were not detected by mammography and therefore could have been missed with mammography alone. The procedure for conducting a CBE was not reported, but the estimated sensitivity (ability of the test to correctly identify those patients with the disease (89)) for CBE was 58.8% and specificity (ability of the test to correctly identify those patients without the disease (89)) was 93.4%, (90) similar to previous estimates. In a Canadian study of 300 000 women aged 50 to 69, CBE increased the rate of detection of small invasive cancers over mammography alone by a small amount, between 2% to 6%. Trained nurses or physicians performed the CBE, which included visual inspection followed by a systematic 10-minute examination.(91) None of these trials showed a significant difference in breast cancer mortality between screening with combined mammography and CBE compared to mammography alone. (92) The USPSTF found a lack of evidence to recommend for or against breast cancer screening with CBE apart from mammography. (93) The utility of CBE as a detection method, however, has relied on its performance characteristics. The variation of CBE techniques performed by clinicians makes it challenging to assess the efficacy of the clinical examination in routine practice, which may not meet the standards of the Canadian trial. Most professional guideline groups advocate incorporating CBE as long as it is performed correctly. Per the ACS recommendations, after visual inspection and palpation of lymph nodes, the examiner should use the pads of the middle three fingers using circular motions, to cover the area down the midaxillary line, across the inframammary ridge at the fifth/sixth rib, up the lateral edge of the sternum, across the clavicle, and back to the midaxilla. A vertical strip pattern is preferred over the concentric circle pattern, and the exam should palpate at increasing levels of pressure (superficial,
intermediate, and deep).(94)

Breast Cancer Screening for Women at High Risk
The recommendations for screening and risk reduction for women at high risk from breast cancer are summarized in Table 4 .
Magnetic Resonance Imaging
In April 2007, the ACS released guidelines on the use of annual breast magnetic resonance imaging (MRI) in addition to mammography for breast cancer screening in women at high risk. This includes women who have an approximate lifetime risk ≥20%; namely, those who are BRCA mutation carriers, first-degree relatives of known BRCA mutation carriers who have not undergone genetic testing, women who received chest irradiation between 10 and 30 years ago, Li-Fraumeni syndrome and firstdegree relatives, Cowden and Bannayan-Riley-Ruvalcalba syndromes and their first-degree relatives.
Insufficient evidence for screening with MRI exists for LCIS, atypical ductal hyperplasia, heterogeneously dense breasts, women with a personal history of breast cancer, or women with a lifetime risk <20%. (95) Although not exclusive to BRCA 1 and 2 carriers, MRI combined with mammography has a higher sensitivity compared to mammography alone (70%-97% and 23%-41%, respectively)(96); however, specificity is lower with the combined method (75%-97%) versus mammography alone (93%-99%) because of the high number of false positives with MRI (96 Various studies have also evaluated screening preferences and differences based on specialty.
In a web-based survey (106) of 11, 922 primary care physicians, over 95% recommended screening mammography to women aged 50-69 years, regardless of specialty. However, for women 40-49 years old, 94% of obstetrician gynecologists always recommended mammography compared to 81% of internal medicine physicians and 84% of family medicine physicians. Similarly, for women ages 70 and older, 86% of obstetrician gynecologists always recommended screening mammography compared to 67% for internal medicine and 59% for family medicine physicians.
Another survey (107) led by the National Cancer Institute asked 1212 primary care physicians about their breast cancer screening practices. The ACS guidelines were cited as the most influential (56%), followed by ACOG (47%), USPSTF (42%), American Academy of Family Physicians (32%), and American College of Physicians (25%) guidelines. More than two-thirds of all physicians recommended mammography to women 40 to 49 annually compared to greater than 90% of all physicians who recommended annual mammography to women 50 years and over. Also, both family medicine and internal medicine physicians were more likely to no longer recommend screening at a certain age (30.2% and 37.8%, respectively) than obstetrician gynecologists (14%). (109) Despite the varying recommendations, ultimately it is the responsibility of the provider to discuss the net harms and benefits of breast cancer screening with each patient to determine individual screening preferences.
Barriers to Delivery
Despite having access to health care, many women are not being screened. (108) Racial disparities in breast cancer include the discrepancy in mortality rates between blacks compared to whites. Cook County (Illinois, USA) investigators who analyzed 25, 900 cases of breast cancer found that black women were more likely to be diagnosed at later stages than white women at any age after evaluating by stage, geocode, race/ethnicity, and socioeconomic status. Hispanic women were also likely to have a later diagnosis than white women up until about age 68. Poverty was also a predictor of being diagnosed with breast cancer at a later stage. (116) In another study, black women had a statistically significant lower 5-year survival rate (55.9%) compared to white women (68.8%). After matching for presentation characteristics, white patients were more likely to receive treatment compared to black patients, mean time from diagnosis to treatment was longer for black patients, and black patients were less likely to receive treatment with chemotherapy and more likely to receive breast-conserving surgery without other treatment compared to white patients. These presentation characteristics accounted for the majority of the difference in the absolute survival rates between black and white women. • Biopsy-confirmed atypical hyperplasia
• Certain inherited genetic mutations for breast cancer (BRCA1 and/or BRCA2)
• Lobular carcinoma in situ
• Mammographically dense breasts
• Personal history of early onset (<40 years) breast cancer
• Two or more first-degree relatives with breast cancer diagnosed at an early age 2.1 -4.0
• Personal history of breast cancer (40+ years)
• High endogenous estrogen or testosterone levels (postmenopausal)
• High dose radiation to chest
• One first-degree relative with breast cancer
• Diethylstilbesterol (DES) exposure
• Early menarche (age <12 years)
• Height (tall)
• High socioeconomic status
• Late age at first pregnancy (age >30 years)
• Late menopause (age >55 years)
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• Never breastfed a child
• No full-term pregnancies
• Obesity (postmenopausal)/adult weight gain • 
List 2. Summary of Recommendations for Primary Prevention for Breast Cancer
Factors that are associated with an increased risk of breast cancer:
• Obesity (weight gain important, weight loss less clear)
• Tobacco (current and previous use)
• Alcohol use (3-14 drinks/week)
Factors that are associated with a decreased risk of breast cancer:
• Physical Activity (moderate to high levels)
• Chemoprevention with SERMS (recommended for women age 35 or older at high risk for breast cancer and at low risk for medication adverse events such as thromboembolic disease)
Factors that are associated with an unknown relation to risk of breast cancer: 
